Lilly's Obesity Pill Heads for Diabetes Filing After Heart Risk Trial
Eli Lilly’s newly approved obesity medication, marketed as Foun…, demonstrated a 16% lower incidence of major cardiovascular events compared with a standard insulin regimen in a recent trial. The data, presented by Lilly, suggest the drug not only aids weight loss but also offers heart‑risk benefits. Leveraging these results, the company plans to submit a regulatory filing to expand the drug’s label to include type 2 diabetes treatment. The move could position the pill as a dual‑action therapy in a crowded metabolic‑disease market.
Freya Biosciences Advances Microbial Treatment for IVF Implantation Failure
Freya Biosciences announced that its microbial immunotherapy designed to address IVF implantation failure has progressed to a Phase 2 mid‑stage trial after demonstrating safety and early efficacy in healthy volunteers. The therapy leverages modulation of the uterine microbiome to improve endometrial...
Scribing Startup Abridge Adds NEJM, JAMA as It Moves Into Medical AI Search
Abridge, the AI‑driven clinical scribing startup, has secured licensing deals with the New England Journal of Medicine and the Journal of the American Medical Association. The integration lets physicians pull peer‑reviewed research into their notes in real time, positioning Abridge...
In Vivo Autoimmune CAR-T Race Grows as Two RNA Startups Enter the Clinic
Two RNA‑focused biotech firms have entered human trials of in vivo CAR‑T therapies targeting autoimmune diseases. China’s Immorna reported its first systemic sclerosis patient treated with an RNA‑delivered CAR‑T that reduced peripheral B‑cell activity. A U.S. startup, GeneCure, launched a...
Biogen Filing Reveals Apellis Deal Details; Telix Raises $600M
Biogen disclosed a $5.6 billion acquisition of Apellis, marking a strategic shift from its traditional neurology focus toward broader rare‑disease and complement‑inhibition platforms. The deal, detailed in a recent SEC filing, includes a mix of cash and stock and is expected...
Former FDA Cancer Chief Pazdur Warns of the Political 'Breach' Of Review Teams
Richard Pazdur, who led the FDA’s oncology review program for more than two decades, stepped down in December after only a few weeks as director of the agency’s Center for Drug Evaluation and Research. In his departure, Pazdur warned that...
Revolution Medicines Prices $2B Raise as XBI Reaches Heights Not Seen Since Pandemic
Revolution Medicines priced a $2 billion public offering, marking the biotech sector’s largest equity raise since the COVID‑19 pandemic. The capital raise follows a recent positive readout from the company’s late‑stage trial, boosting investor confidence. The move helped lift the SPDR...
Updated: FDA Asks for Data on Lilly’s Foundayo to Assess Heart, Liver Risks
The U.S. Food and Drug Administration has asked Eli Lilly for additional safety data on its newly approved obesity medication, Foundayo. The agency is specifically seeking information on any cardiovascular events and liver‑related adverse effects observed in clinical trials and post‑marketing...
Replimune Looks Ahead as Repeat CRL Speeds the Company's Decline
Replimune received a second complete response letter (CRL) from the FDA for its lead oncolytic cancer therapy, citing additional data gaps and manufacturing concerns. The regulatory setback triggered a wave of layoffs affecting roughly 30% of its workforce and pushed...
Revolution Medicines Leads Latest Wave of Stock Offerings, Totaling $1.5B
Revolution Medicines anchored a fresh wave of biotech equity offerings on Monday, helping to lift total capital raised to roughly $1.5 billion. The offering round also included Spyre Therapeutics and Allogene Therapeutics, each filing separate share sales. Proceeds are earmarked for...
Endpoints Biopharma Sentiment Survey for Q2 2026
Endpoints Signal is launching its Q2 2026 Biopharma Sentiment Index (BPSI) survey, a three‑minute questionnaire that aggregates insider views into a quarterly benchmark. More than 1,000 biopharma professionals participated in the previous quarter, providing a snapshot of sentiment on pipelines, pricing...
Harbinger Raises $100M; Astellas to Close Seattle Site
Harbinger Health announced a $100 million financing round led by Flagship Pioneering to fast‑track its next‑generation cancer‑detection platform. The capital will fund expanded clinical trials, scale manufacturing, and pursue regulatory clearance for its early‑stage diagnostic test. Harbinger positions its technology as...
J&J Increasingly Confident It Can Manage Stelara Cliff, but Work Remains
Johnson & Johnson says the most intense biosimilar pressure on its blockbuster drug Stelara is largely behind it, and the company now projects robust growth through the late 2020s. Executives cite new therapeutic indications, expanded global reach, and strategic pricing...
Eli Lilly to Pay up to $300M for Cancer Biotech CrossBridge Bio
Eli Lilly announced it will acquire antibody‑drug conjugate (ADC) developer CrossBridge Bio for up to $300 million, combining an upfront cash payment with milestone‑based earn‑outs. CrossBridge, founded by biotech veteran Michael Torres, brings a proprietary ADC platform and a lead oncology candidate currently in...
Parker Institute Doubles Down on Cancer Vaccines as Part of Ongoing Reboot
The Parker Institute for Cancer Immunotherapy announced a renewed focus on mRNA‑based cancer vaccines, launching a multi‑year program that will fund clinical trials and partner with biotech firms. The initiative includes a $200 million investment pool aimed at accelerating vaccine design,...
